Adaptive Biotechnologies Corp
ADPT
Market Cap$548.21M
Close$
$3.64
0.8% upside
Current Fair Value
0.8% upsideUndervalued by 0.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $548.21 Million |
|---|---|
| Enterprise Value | $239.34 Million |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-1.48 |
| Beta | 2.09 |
| Outstanding Shares | 147,368,324 |
| Avg 30 Day Volume | 1,698,057 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -2.55 |
|---|---|
| PEG | 14.43 |
| Price to Sales | 3.61 |
| Price to Book Ratio | 3.61 |
| Enterprise Value to Revenue | 1.37 |
| Enterprise Value to EBIT | -1.24 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
ESG Score
No data
About Adaptive Biotechnologies Corp
CEO: Chad Robins Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Adaptive Biotechnologies believes the adap...